CardiomyopathyUsefulness of High-Sensitivity Cardiac Troponin T and Brain Natriuretic Peptide as Biomarkers of Myocardial Fibrosis in Patients With Hypertrophic Cardiomyopathy
Section snippets
Methods
The present study consisted of consecutive patients with HC who were referred to our institute for gadolinium-enhanced myocardial resonance imaging from March 2010 to March 2013. The diagnosis of HC was based on the conventional echocardiographic demonstration of left ventricular end-diastolic thickness ≥15 mm and left ventricular end-diastolic diameter ≤55 mm in the absence of any cardiac or systemic disorder that could cause hypertrophy, such as severe hypertension or aortic stenosis.
Results
Late gadolinium enhancement was detected in 23 of 53 patients (43%). The location of late gadolinium enhancement was the anterior ventricular septum–free wall junction in 12 patients (23%), the ventricular septum in 11 (21%), the apical area in 9 (17%), the posterior ventricular septum–free wall junction in 4 (8%), the anterior wall in 4 (8%), the posterior wall in 2 (4%), and the lateral wall in 1 (2%). Late gadolinium enhancement was associated with younger age, a lower left ventricular
Discussion
The present study showed that higher levels of serum hs-cTnT and plasma BNP were associated with late gadolinium enhancement on magnetic resonance imaging in patients with HC. Furthermore, a level of hs-cTnT ≥0.007 ng/ml or BNP ≥70 pg/ml had good diagnostic value for the detection of late gadolinium enhancement, with sensitivity of 96% or specificity of 90% with the combination of the 2 biomarkers. These findings indicate that the combined measurement of hs-cTnT and BNP could be a favorable
Disclosures
The authors have no conflicts of interest to disclose.
References (29)
- et al.
The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy
J Am Coll Cardiol
(2004) - et al.
Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy
J Am Coll Cardiol
(2010) - et al.
Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy
J Am Coll Cardiol
(2010) - et al.
Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy
JACC Cardiovasc Imaging
(2012) - et al.
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
J Am Coll Cardiol
(2011) - et al.
Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling
J Am Coll Cardiol
(2009) - et al.
Serum adipokine zinc α2-glycoprotein and lipolysis in cachectic and noncachectic heart failure patients: relationship with neurohormonal and inflammatory biomarkers
Metabolism
(2012) - et al.
Serum levels of high-sensitivity troponin T: a novel marker for cardiac remodeling in hypertrophic cardiomyopathy
J Card Fail
(2010) - et al.
Variables associated with contrast-enhanced cardiovascular magnetic resonance in hypertrophic cardiomyopathy: clinical implications
J Card Fail
(2008) - et al.
Significance of plasma levels of N-terminal Pro-B-type natriuretic peptide on left ventricular remodeling in non-obstructive hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene
Am J Cardiol
(2008)
Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure
Am Heart J
Improving the primary prevention of cardiovascular events by using biomarkers to identify individuals with silent heart disease
J Am Coll Cardiol
Troponin: messenger or actor?
J Am Coll Cardiol
Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy
J Cardiovasc Magn Reson
Cited by (0)
See page 871 for disclosure information.